Guggenheim maintains Amgen at Neutral, raises price target to $435 from $378

What happened

Guggenheim kept its rating on Amgen at Neutral and raised its price target to $435 from $378, a 15.1% increase. The new target is 9.1% below Amgen’s Nov. 4 closing price of $478.48.

Confirmed

Global impact / market context

The higher target signals a less negative valuation view than Guggenheim’s earlier target, but it still sits below the cited closing price. If investors give the target weight, it could shape expectations for Amgen shares and, through share valuation, influence the company’s ability to raise funds or fund investment.

Analyst inference

The five most recent analyst notes over the past 30 days set targets from $425 to $530, putting Guggenheim’s $435 near the lower end. Ratings range from Hold and Neutral to Buy and Sector Outperform, showing differing views on Amgen.

Confirmed

What to watch

1. Compare future analyst targets with Guggenheim’s $435 and the reported $425–$530 range to see whether the spread among published views narrows or widens. Analyst inference
2. Watch for any change in Guggenheim’s Neutral rating or target; the article reports no change to the rating alongside the target increase. Confirmed
3. Track Amgen’s share price against the target levels cited here; movement could alter the implied gap between the shares and analysts’ expectations. Analyst inference

Evidence

• Original source link unavailable